Arca
Skip to content
Tools
Tools

CCR4: C-C chemokine receptor type 4

High affinity receptor for the C-C type chemokines CCL17/TARC, CCL22/MDC and CKLF isoform 1/CKLF1.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on CCR4, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 1

Approved1

  • Mogamulizumab

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        MogamulizumabApprovedKyowa KirinAntibodyCross-linking agentC-C chemokine receptor type 4 cross-linking agent11

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        A Study of VG712 in Patients With Mycosis FungoidesMogamulizumabPhase 2Not yet recruitingVirogen Biotechnology Inc.Apr 14, 2026
        Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result SurveillanceMogamulizumab—RecruitingKyowa Kirin Co., Ltd.Aug 20, 2025
        A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care MogamulizumabMogamulizumab—RecruitingCity of Hope Medical CenterJun 4, 2025
        A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1MogamulizumabPhase 2RecruitingMemorial Sloan Kettering Cancer CenterNov 20, 2024
        Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell LymphomaMogamulizumabPhase 2RecruitingYale UniversityAug 18, 2023
        Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell LymphomasMogamulizumabPhase 2RecruitingUniversity of Michigan Rogel Cancer CenterJul 21, 2023
        Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell LymphomaMogamulizumabPhase 2RecruitingCity of Hope Medical CenterJun 18, 2021
        Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/LymphomaMogamulizumabPhase 1RecruitingJohn ReneauApr 19, 2021

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        Neoplasm
        0.42
        Primary cutaneous T-cell non-Hodgkin lymphoma
        0.36
        Trauma complication
        0.33
        Hypothyroidism
        0.25
        Childhood onset asthma
        0.24
        Head and neck squamous cell carcinoma
        0.21

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2414, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P51679, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.